Quantify Neuroimmune Biomarkers to Improve Clinical Trial Outcomes

Improving clinical trial outcomes in neuroimmune drug development requires more than identifying biomarkers; it depends on the ability to quantify them with precision and translate those measurements into actionable insights. Yet many programs still struggle to connect biomarker data to meaningful clinical endpoints, limiting their impact on trial success.

This webinar will explore how ultrasensitive biomarker quantification is transforming neuroimmune clinical trials by enabling more reliable measurement of disease biology in both cerebrospinal fluid (CSF) and blood. Using advanced digital immunoassay technology, researchers can now detect low-abundance proteins at femtogram-per-milliliter concentrations, achieving up to 900× greater sensitivity than conventional ELISA approaches. This level of sensitivity supports precise, reproducible biomarker measurement, even when changes are subtle but clinically significant.

Attendees will learn how key neuroimmune biomarkers, including neurofilament light (NfL), GFAP, sTREM-2 and YKL-40, are being applied to improve clinical trial outcomes. These biomarkers offer valuable insight into neuroaxonal injury, astrocytic damage and microglial activation, enabling their use in patient stratification, treatment monitoring and as pharmacodynamic or surrogate endpoints. Real-world examples demonstrate how blood-based biomarkers are increasingly supporting earlier and more confident decision-making in clinical development.

The session will also address challenges in detecting low-level cytokines and emerging biomarker classes, such as extracellular vesicles, and how ultrasensitive and custom assays are expanding the range of measurable targets. These advances are enabling deeper insight into target engagement, immune modulation and disease progression across clinical studies.

Finally, the featured speaker will discuss how integrating biomarker strategies across discovery, translational research and clinical trials can help reduce uncertainty, improve endpoint selection and ultimately increase the likelihood of trial success. Attendees will leave with a clearer understanding of how to leverage quantitative neuroimmune biomarkers to drive better clinical trial outcomes and accelerate therapeutic development.

Register for this webinar to learn how neuroimmune biomarker quantification can reduce uncertainty, improve endpoint selection and support stronger clinical trial decisions.

Speaker

Sannette Hall, PhD, Senior Field Applications Scientist, Quanterix

Sannette Hall, PhD, is a Senior Field Applications Scientist at Quanterix, specializing in ultrasensitive biomarker detection for translational and clinical research. She supports biopharma and academic partners in applying digital immunoassay technologies to advance biomarker-driven drug development in neurology and immunology. Her expertise spans assay development, biomarker strategy and translating low-abundance protein signals into actionable clinical insights, particularly in neuroimmune and neurodegenerative diseases.

Message Presenter